Safety of biologics in severe asthmatic patients with SARS-CoV-2 infection: A prospective study.

Sara Manti Alessandro GiallongoGiulia PecoraGiuseppe Fabio ParisiMaria PapaleEnza MulèDonatella AloisioNovella RotoloSalvatore Leonardi

Published in: Pediatric pulmonology (2023)

We showed that the scheduled dose of the biologic therapy can be administered safely on time in patients with SARS-CoV-2 infection, as the treatment did not result in adverse events or outcomes.

Keyphrases

respiratory syndrome coronavirus
rheumatoid arthritis
early onset
lung function
stem cells
chronic obstructive pulmonary disease
cystic fibrosis
coronavirus disease
insulin resistance